{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","lowerLimit":"5.68","upperLimit":"9.33","value":"7.4"},{"groupId":"OG001","lowerLimit":"5.82","upperLimit":"10.84","value":"7.5"},{"groupId":"OG002","lowerLimit":"5.65","upperLimit":"9.33","value":"7.3"},{"groupId":"OG003","lowerLimit":"4.80","upperLimit":"7.39","value":"5.7"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"319"},{"groupId":"OG001","value":"302"},{"groupId":"OG002","value":"132"},{"groupId":"OG003","value":"323"}],"units":"Participants"}],"description":"European Organisation for Research and Treatment of Cancer (EORTC) 30-item core quality of life questionnaire (QLQ-C30), which consists of 30 questions combined to produce a global health status/QoL scale. Higher scores indicate better health. A clinically meaningful deterioration is defined as a decrease in the score from baseline of ≥10. Time to deterioration is defined as the time from the date of randomization until the date of the first clinically meaningful deterioration that is confirmed at a subsequent visit or death by any cause in the absence of a clinically meaningful deterioration, regardless of whether the patient discontinues study drug(s) or receives another anticancer therapy.","dispersionType":"95% Confidence Interval","groups":[{"description":"Durvalumab 1500 mg every 4 weeks (Q4W)","id":"OG000","title":"Durva 1500 mg"},{"description":"Tremelimumab 300 mg × 1 dose + durvalumab 1500 mg Q4W","id":"OG001","title":"Treme 300 mg x1 Dose + Durva 1500 mg"},{"description":"Tremelimumab 75 mg Q4W × 4 doses + durvalumab 1500 mg Q4W","id":"OG002","title":"Treme 75 mg x4 Doses + Durva 1500 mg"},{"description":"Sorafenib 400 mg twice daily (BID)","id":"OG003","title":"Sora 400 mg"}],"paramType":"MEDIAN","populationDescription":"A subset of the FAS who had baseline scores of \\>=10. T75+D arm was closed during study.","reportingStatus":"POSTED","timeFrame":"At baseline and every 8 weeks for the first 48 weeks and then every 12 weeks thereafter until death or the final analysis DCO (27Aug2021), assessed up to approximately 46 months.","title":"EORTC QLQ-C30 Time to Global Health Status/QoL Deterioration","type":"SECONDARY","unitOfMeasure":"months"}